BPC-157 5mg

BPC-157 5mg: Background and Research Context

BPC-157 (Body Protection Compound-157) is a synthetic peptide fragment based on a sequence identified within human gastric juice in the early 1990s by researchers investigating naturally occurring gastroprotective proteins. Unlike many research peptides derived from hormone or growth-factor families, BPC-157's origin as a "stable gastric pentadecapeptide" is what first drew laboratory interest — the parent protein appeared to survive gastric conditions that degrade most peptides rapidly, which made its stability and mechanism a subject of ongoing preclinical study.

Since then, BPC-157 has become one of the most widely studied peptides in preclinical research literature, with published in-vitro and animal-model studies examining its effects on angiogenesis (blood vessel formation), tissue and tendon-cell behaviour, gut-barrier integrity, and interactions with nitric oxide signalling pathways. It is important to note that this body of evidence is almost entirely preclinical — cell-culture and animal-model research — and BPC-157 has not been approved by the MHRA, FDA, or any equivalent regulator for human therapeutic use. It is not licensed as a medicine anywhere.

Product Name: BPC-157 5mg Molecular Formula: C62H98N16O22 Molecular Weight: 1419.6 g/mol Purity: ≥99% (batch-specific COA provided) Sequence: H-Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val-OH Form: Lyophilised solid, supplied in sealed vial

What the Research Literature Actually Covers

Researchers commonly cite BPC-157 preclinical studies in the following areas:

• Tendon and ligament cell research — in-vitro studies on fibroblast migration and tendon explant models
• Gastrointestinal research — the compound's original discovery context, including gut lining and mucosal models
• Angiogenesis research — animal-model studies on blood vessel formation pathways
• Nitric oxide pathway research — proposed mechanism studies relating to vascular signalling
• Musculoskeletal research models — rodent studies on soft-tissue recovery markers

None of this constitutes evidence of safety or efficacy in humans, and Flex Peptides makes no such claim. This section is provided for research context only, sourced from publicly available preclinical literature; researchers should review primary sources directly before drawing conclusions.

Storage and Handling

Store the lyophilised vial as specified on the product label and accompanying documentation — protected from light, moisture, and temperature fluctuation. Once reconstituted for laboratory use, peptide stability is time- and temperature-dependent; researchers should follow their own institution's laboratory protocols and the compound-specific storage guidance in the literature rather than generic timelines. All handling should follow standard laboratory practice and appropriate PPE.

Quality Assurance

Every batch of BPC-157 sold by Flex Peptides is independently tested by third-party laboratory analysis (HPLC/MS), with the Certificate of Analysis for this specific batch available in the image gallery above. We publish batch-specific COAs rather than generic ones so researchers can verify the exact purity and identity of the vial they receive.

Why Flex Peptides

Flex Peptides is a UK-based supplier focused on peptide research materials with transparent sourcing and batch-level documentation. Every product ships with COA access, and our specifications are drawn from the same analytical data provided to customers — not marketing copy layered on top of it.

Research-Use & Legal Information

BPC-157 5mg is supplied strictly for laboratory and in-vitro research use. It is not intended for human or veterinary consumption, clinical use, diagnosis, treatment, prevention of disease, or dietary supplementation. Researchers are responsible for ensuring their use complies with UK law, institutional protocols, and any applicable licensing requirements. By purchasing, you confirm you are a qualified researcher and agree to Flex Peptides' terms of sale.